XML 42 R22.htm IDEA: XBRL DOCUMENT v3.19.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Schedule of components of deferred tax assets and liabilities
  2018   2017 
Deferred tax assets:        
Net operating losses carry forward  $34,531,577   $30,826,534 
Share-based compensation   2,950,963    3,731,413 
Research and development/orphan drug credits   8,896,703    6,324,998 
Others   15,285    11,369 
Less: valuation allowance   (46,394,528)   (40,894,314)
           
Deferred tax assets, net  $-   $- 
Schedule of difference between income tax provision and U.S federal statutory rate
   For the year ended 
   December 31,
2018
   December 31,
2017
   December 31,
2016
 
                         
Federal statutory income taxes  $(4,967,332)   (21.0)%  $(9,044,420)   (34.0)%  $(8,269,386)   (34.0)%
State income taxes   1,413,678    6.0%   (1,940,945)   (7.3)%   973,547    4.0%
Change in federal statutory rate   -    -%   17,939,714    67.4%   -    -%
Deferred true-up   -    -%   3,090,816    11.8%   (10,511,380)   (43.3)%
Research and Development/Orphan Drug Tax Credit   (1,986,609)   (8.4)%   (3,029,074)   (11.4)%   (141,769)   (0.6)%
Unrealized derivative gain/loss   -    -%   (120,870)   (0.5)%   (956,840)   (3.9)%
Other   40,049    0.2%   12,845    0.0%   13,632    0.1%
Change in valuation allowance   5,500,214    23.2%   (6,908,066)   (26.0)%   18,892,196    77.7%
                               
Provision for income tax  $-    -   $-    -   $-    -